Phase 3 Readout

Phase 3 Topline: A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Che

Indication
Gastroesophageal Junction Adenocarcinoma; Gastric Cancer

Other upcoming events for AMGN

Phase 2 StartPhase 2 Start: Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safe
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pemb
Phase 3 ReadoutPhase 3 Topline: A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Ef
Phase 3 ReadoutPhase 3 Topline: PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatmen
Phase 3 ReadoutPhase 3 Topline: Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Che — AMGN Phase 3 Readout | BioSniper